Colinz Laboratories (BOM:531210) Total Liabilities: ₹0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:531210 Colinz Laboratories Ltd BOM:531210
60 GF Score
Price ₹78.43
GF Value ₹42.58
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Colinz Laboratories Total Liabilities?

Colinz Laboratories BOM:531210 +2.50% 60 Total Liabilities is ₹0.00 Mil as of Jun. 2026. GuruFocus rates BOM:531210 with a GF Score™ of 60/100 and a GF Value™ of ₹42.58 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Colinz Laboratories's Total Liabilities for the quarter that ended in Jun. 2026 was ₹0.00 Mil.

Colinz Laboratories's quarterly Total Liabilities declined from Sep. 2025 (₹22.49 Mil) to Dec. 2025 (₹0.00 Mil) but then stayed the same from Dec. 2025 (₹0.00 Mil) to Jun. 2026 (₹0.00 Mil).

Colinz Laboratories's annual Total Liabilities increased from Mar. 2023 (₹20.92 Mil) to Mar. 2024 (₹24.11 Mil) but then declined from Mar. 2024 (₹24.11 Mil) to Mar. 2025 (₹23.43 Mil).

Colinz Laboratories Total Liabilities Historical Data

* Premium members only.

The historical data trend for Colinz Laboratories's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Colinz Laboratories Total Liabilities Chart

Colinz Laboratories Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.11 22.44 20.92 24.11 23.43

Colinz Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Jun26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.43 0.00 22.49 0.00 0.00
BOM:531210
60GF Score
Colinz Laboratories Ltd BOM:531210
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Colinz Laboratories Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Colinz Laboratories's Total Liabilities for the fiscal year that ended in Mar. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=21.624+(0+1.806
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=23.43

Total Liabilities=Total Assets (A: Mar. 2025 )-Total Equity (A: Mar. 2025 )
=118.174-94.744
=23.43

Colinz Laboratories's Total Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=N/A

Total Liabilities=Total Assets (Q: Jun. 2026 )-Total Equity (Q: Jun. 2026 )
=N/A-N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of ₹0.00 Mil mean?
Colinz Laboratories (BOM:531210) has a Total Liabilities of ₹0.00 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Colinz Laboratories and its competitors.
Is Colinz Laboratories' Total Liabilities too high?
Colinz Laboratories' current Total Liabilities is ₹0.00 Mil. Overall, Colinz Laboratories has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Colinz Laboratories' Total Liabilities compare to ZTS?
Colinz Laboratories' Total Liabilities of ₹0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Colinz Laboratories and its competitors. Colinz Laboratories's current Total Liabilities is ₹0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Colinz Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Colinz Laboratories (BOM:531210) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹42.58, compared to a current price of ₹78.43 — trading 84.2% above its estimated fair value. The current Total Liabilities is ₹0.00 Mil. Colinz Laboratories' overall GF Score™ is 60/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Colinz Laboratories (BOM:531210), the current Total Liabilities is ₹0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Colinz Laboratories (BOM:531210) Overvalued in 2026?

Based on GuruFocus' analysis, Colinz Laboratories stock appears to be overvalued. The current stock price of ₹78.43 is trading 84.2% above its estimated GF Value™ of ₹42.58. GuruFocus considers Colinz Laboratories to be Significantly Overvalued.

Key valuation signals for BOM:531210:

  • Total Liabilities: ₹0.00 Mil
  • GF Value™: ₹42.58 vs. price of ₹78.43 (84.2% above fair value)
  • GF Score™: 60/100 with 7 warning signs

No single metric tells the full story. See the BOM:531210 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Colinz Laboratories Business Description

Address Mulund Goregaon Link Road, A-101 Pratik Industrial Estate, Next to Fortis Hospital, Bhandup (West), Mumbai, MH, IND, 400078
Colinz Laboratories Ltd is an India-based company engaged in manufacturing and trading in Pharmaceutical formulations. It offers formulations in the products category of ayurvedic, allopathic, and nutraceuticals. The company manufactures pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, injectables, ointments, creams, and others. It also has certain specialized products for gynecology, cardiology, gastroenterology, and others. The group derives revenue from the sale of its products in India.
60GF Score

Get the complete analysis for BOM:531210

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹78.43
Price
₹42.58
GF Value